The NIH now funds nearly $20M annually in SUDEP research. Leaders at the NIH credit CURE Epilepsy’s early, modest projects as the initial spark that generated exponential interest and investment at the federal level. That is the type of foundational impact that CURE Epilepsy has year over year.
SUDEP is one of the most devastating but least talked about consequences of epilepsy. Every year it impacts over 1 in 1,000 people living with epilepsy (Sveinsson et al. 2020 Neurology), and countless more when you consider these individuals’ families and friends who suffer untold grief and sadness from the loss of a loved one.
In response to this unacceptable loss, CURE Epilepsy, with the assistance of many parents who were seeking answers, launched the first-ever private research program dedicated to advance the understanding SUDEP and its prevention in the US.
Established in 2004, our cutting-edge SUDEP program impacts include:
“CURE Epilepsy’s contribution to understanding the risk of sudden death in epilepsy has been early, sustained, and transformative. From a handful of case reports 20 years ago to over 200 scientific publications in 2021, CURE Epilepsy’s support of individual investigators provided the engine to develop advanced basic and clinical collaborators. We all owe CURE Epilepsy our gratitude for its continuing leadership in accelerating this effort.”
Jeff Noebels, MD, PhD Baylor College of Medicine